Array

Research

Positive on Mphasis, Infosys; Recommend Alembic Pharma: Abhimanyu Sofat, IIFL 

| July 16 2019 12 : 03 IST | Economic Times - Mumbai

"We have been recommending Alembic Pharma where we are seeing 17 percent growth and free cash flow improvement of Rs 50 crore going up to Rs 200 crore next year and in two years, going to around Rs 400 crore," says Abhimanyu Sofat, Head of Research at IIFL Securities. 

As a house, we believe that Infosys has a better risk reward as compared to TCS. However, it is the mid-cap companies like Mphasis where the upside is likely to be better since multiples are at a significant discount to these companies and the earnings growth is expected to be pretty good. In the pharma space, despite the correction, we are not that bullish on Sun Pharma as of now. We would prefer some of the mid-cap stocks. We have been recommending Alembic Pharma where we are seeing 17 per cent growth and free cash flow improvement of Rs 50 crore going up to Rs 200 crore next year and in two years, going to around Rs 400 crore. It is more of a bottoms up kind of an approach within the pharmaceutical sector and as of now, Sun continues to be negative. 

    Media Kit

    IIFL, serving more than 3.5 million customers

    Looking for a product?

    Submit